Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease (COMPASS)
This study is ongoing, but not recruiting participants.
First Posted: January 28, 2013
Last Update Posted: September 1, 2017
Hamilton Health Sciences Corporation, Population Health Research Institute
Janssen Research & Development, LLC
Information provided by (Responsible Party):